TAVR

¿Deberíamos adoptar el uso rutinario del ultrasonido para guiar el acceso femoral?

Should We Use Ultrasound Routinely to Guide Transfemoral Access?

Currently, transfemoral access (TFA) is used in large-caliber procedures and when transradial access fails. The introduction of ultrasound (US) to guide access has emerged as a technique that allows for precise channeling, avoiding accesses above or below the inguinal ligament. However, evidence regarding the use of this tool has shown diverse results. Two surveys conducted<a href="https://solaci.org/en/2024/02/24/should-we-use-ultrasound-routinely-to-guide-transfemoral-access/" title="Read more" >...</a>

El éxito de la angioplastia sobre las CTO por reestenosis disminuye la mortalidad cardíaca

Recurrent Revascularization at 10 Years after Percutaneous Treatment of DES In-Stent Restenosis

In stent restenosis (ISR) continues to be the main limitation to the percutaneous treatment of coronary artery disease, with 5 to 10% prevalence after new generation DES stenting. Guideline recommendations for this intervention include new DES stenting and the use of drug coated balloons (DCB). Recurrent ISR stenting rate ranges between 10 and 40%, and<a href="https://solaci.org/en/2024/02/22/recurrent-revascularization-at-10-years-after-percutaneous-treatment-of-des-in-stent-restenosis/" title="Read more" >...</a>

PCI Evolution in Infiltrative Diseases

Infiltrative diseases (ID) consist of a heterogeneous series of genetic conditions that cause infiltration and extracellular deposits which alter the diverse systems and organs affected.&nbsp;&nbsp;&nbsp; Amyloidosis, sarcoidosis and hemochromatosis affect the heart, altering the myocardium and the conduction system.&nbsp; PCI is often used at present to treat heart disease, and some of these patients present<a href="https://solaci.org/en/2024/02/21/pci-evolution-in-infiltrative-diseases/" title="Read more" >...</a>

Función de la mano luego del acceso radial distal, ¿es seguro?

KODRA Registry: Distal Radial Access as First Choice in Coronary Procedures

The first experiences with distal radial access (DRA) have revealed significant benefits compared against the transradial approach (TRA), showing reduced bleeding events and better puncture site occlusion rate. Even the spectrum of diseases treated with DRA has grown, and now includes chronic total occlusion (CTO) though 7Fr inductors, such as Terumo’s Glidesheath Slender. The aim<a href="https://solaci.org/en/2024/02/20/kodra-registry-distal-radial-access-as-first-choice-in-coronary-procedures/" title="Read more" >...</a>

Sobrevida en pacientes con insuficiencia tricuspídea según variables clínicas y ecocardiográficas (Clusters)

Should We Treat Obstructive Coronary Artery Disease in TAVI?

Coronary artery disease, both obstructive and non-obstructive, often coexists with significant aortic stenosis. Therapeutic decision-making in this scenario remains controversial, not only regarding the need for treatment, but also about when it should be addressed, considering its pros and cons. Various analyses have yielded contradictory data, as most lesions are chronic and stable. Currently, the<a href="https://solaci.org/en/2024/02/07/should-we-treat-obstructive-coronary-artery-disease-in-tavi/" title="Read more" >...</a>

Cierre de orejuela izquierda

Left Atrial Appendage Closure and Concomitant Transcatheter Intervention: Can We?

Several scientific societies support performing left atrial appendage occlusion (LAAO) as a stand-alone procedure, even though it is often associated to other cardiomyopathies requiring transcatheter intervention.&nbsp; Though still controversial, combining LAAO and any other cardiac intervention might reduce hospitalizations, as well as the need for additional punctures, anesthesia, red tape, a longer stay and higher<a href="https://solaci.org/en/2024/02/06/left-atrial-appendage-closure-and-concomitant-transcatheter-intervention-can-we/" title="Read more" >...</a>

pacemaker marcapasos definitivo

Benefit of Cusp overlap method for self‐expanding transcatheter aortic valves

The need for permanent pacemaker implantation (PPM) continues to be one of the main challenges in TAVR, especially with self-expanding valves, with a pacemaker implantation rate that varies between 17.5% and 30% in large randomized studies, vs. 4% to 6.5% with self-expanding valves. Therefore, in an attempt to prevent the need for PPM implantation, the<a href="https://solaci.org/en/2024/02/02/benefit-of-cusp-overlap-method-for-self%e2%80%90expanding-transcatheter-aortic-valves/" title="Read more" >...</a>

Costo efectividad de la reparación endovascular y quirúrgica en aneurismas complejos

Promising Results of Transcatheter Mitral Valve Replacement in Bioprosthesis Failure

Failure of a mitral bioprosthesis always poses a challenge regarding decision-making, especially when dealing with elderly patients with multiple risk factors. The scenario is worsened by the high risk associated with a new sternotomy and the significant impact of undergoing new surgery. Transcatheter mitral valve-in-valve (TMViV) replacement is emerging as a valid strategy in the<a href="https://solaci.org/en/2024/02/01/promising-results-of-transcatheter-mitral-valve-replacement-in-bioprosthesis-failure/" title="Read more" >...</a>

Events According to Revascularization Modality in the ISCHEMIA Trial

The main studies carried out on patients with chronic coronary syndromes (CCS), such as the MASS II, COURAGE, BARI 2D and FAME-2, failed to show benefits in terms of mortality with the invasive approach.&nbsp; The ISCHEMIA, a large randomized study including patients with moderate to severe ischemia, with without left main disease and with acceptable<a href="https://solaci.org/en/2024/01/31/events-according-to-revascularization-modality-in-the-ischemia-trial/" title="Read more" >...</a>

Balancear el riesgo de sangrado vs trombótico para definir el tiempo de doble antiagregación

Clopidogrel Monotherapy Beyond 12 months: Long Term Analysis of the STOPDAPT-2

Short dual antiplatelet therapy (DAPT) has shown benefits in patients receiving drug eluting stents (DES), reducing bleeding with no concomitant increase in major adverse cardiovascular events (MACE). Traditionally, the therapeutic window was limited to monotherapy with P2Y12 inhibitors during the first year and there are few data on short DAPT followed by long term monotherapy<a href="https://solaci.org/en/2024/01/29/clopidogrel-monotherapy-beyond-12-months-long-term-analysis-of-the-stopdapt-2/" title="Read more" >...</a>

Top